OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomasMichael Platten, Wolfgang Wick, J Hense et al.|Neuro-Oncology|2018Cited by 3